Researchers are studying a potential treatment to prevent or reduce symptoms of psychosis in people with Alzheimer’s Disease.
The investigational study drug used in the Alzheimer’s Disease with Psychosis Study is FDA approved to potentially treat symptoms of psychosis in Schizophrenia patients. Safety is one of the top priorities.
The study drug is in Phase 3. A Phase 3 study medication has already been tested on a large population of patients. This study involves taking an oral capsule, daily for the duration of the study.
The total duration of treatment is approximately 40 weeks with a Screening and Safety Follow-up period.
Sign Up
Frequently Asked Questions
What is a research study?
A research study (also called a clinical trial) is a medical study that helps to answer important questions about an investigational drug – these may include how well an investigational study drug works for a certain condition. All medications must be tested in clinical research studies before they can be approved and prescribed to patients.
Why should I participate in research studies?
A research study is the process by which new and innovative medications, interventions and treatments are approved and brought to market. Even over-the-counter medications, such as NSAIDs, you may have used to counteract a headache, have gone through the clinical research study process before it was available at your local pharmacy. In the Alzheimer’s Disease with Psychosis Study, the participant will receive care at no cost, have specialist physicians guide you throughout the clinical trial without needing health Insurance, and potentially aid in finding a treatment for psychosis symptoms for Alzheimer’s Disease.
What is the purpose of the Alzheimer’s Disease with Psychosis Study?
The Alzheimer’s Disease with Psychosis Study is researching an investigational study drug that may help prevent or reduce symptoms of psychosis in people with Alzheimer’s disease.
What will the Alzheimer’s Disease with Psychosis Study involve?
The Alzheimer’s Disease with Psychosis Study will enroll participants throughout North America and Europe. The total duration of treatment is approximately 40 weeks which will include visits to a study center near the participant’s home.
Is there a cost to participate?
There is no cost to participate in the Alzheimer’s Disease with Psychosis Study. If you qualify, all study-related care will be provided by a team of doctors, nurses and study staff at no cost to you or your insurance.
How far is the study center?
The Alzheimer’s Disease with Psychosis Study is currently processing volunteers in Arizona, California, Colorado, Florida, Louisiana, Michigan, New York, Ohio, South Carolina, Texas and more. Sign up to see if you qualify.
What is the process to participate?
Fill out the online questionnaire to assess your pre-qualification. Your information will be used to match you to a Clinical Trial. Discover your pre-qualification status. A medical representative will reach out by phone to go deeper into the study and address your questions. The participant will reconfirm their interest in participation. Get connected with a research center for the next steps.
What if I have more questions?
The research team will be able to explain more about what the Alzheimer’s Disease with Psychosis Study will involve, and it is up to you to decide if you want to take part. Participation in this study is voluntary. If you decide to participate, you are free to withdraw at any time without affecting those relationships.